Equities
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.005
  • Today's Change0.00 / 0.00%
  • Shares traded559.23k
  • 1 Year change-28.57%
  • Beta0.8266
Data delayed at least 20 minutes, as of Jun 03 2024 07:10 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.

  • Revenue in AUD (TTM)123.46k
  • Net income in AUD-12.28m
  • Incorporated1997
  • Employees11.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Rhythm Biosciences Ltd157.67k-8.63m17.65m----12.90--111.95-0.0386-0.03860.00070.00550.0263--1.81---144.00-106.11-169.71-125.51-1,899.74-1,210.71-5,473.20-6,642.262.04--0.0304--814.1828.776.55---20.43--
Auscann Group Holdings Ltd2.05m-9.44m17.76m27.00------8.67-0.0213-0.02170.00430.01620.1674--5.35---77.15-39.85-78.72-40.73100.59---460.74-925.91---23.160.00--13.8851.3757.10------
Lumos Diagnostics Holdings Ltd12.39m-13.30m17.81m----1.28--1.44-0.0357-0.03570.03520.02890.34182.246.37---36.70-40.15-55.14-56.6759.7345.97-107.38-162.900.479-6.250.4803---9.4239.2980.38---38.50--
Algorae Pharmaceuticals Ltd84.10k-2.25m18.56m----5.12--220.71-0.0015-0.00150.000060.00220.0245--1.79---65.51-46.12-70.91-53.52-----2,678.04-591.05---136.750.00--1,132.26-44.06-7.68------
LBT Innovations Limited2.00m-21.38m18.77m17.00--6.91--9.37-0.0428-0.04280.00380.0020.10870.08192.25117,882.40-115.89-28.85-131.86-30.9994.76---1,066.62-441.763.30-6.850.5633---5.29-18.45-239.17---34.63--
Amplia Therapeutics Ltd1.87m-4.46m19.01m1.00--0.9472--10.18-0.0224-0.02240.00940.07390.0949--0.7018---22.64-25.27-26.24-26.78-----238.69-342.26----0.1318---42.1012.31-71.30--31.88--
Immuron Ltd3.58m-3.88m21.43m6.00--1.22--5.99-0.017-0.0170.01570.07690.16640.64687.92596,106.70-18.06-27.48-19.86-29.5880.8777.52-108.52-296.647.79-2.850.0023--135.85-13.34-32.66--3.27--
BPH Energy Ltd345.67k894.65k22.95m2.00k20.410.9868--66.400.0010.0010.00040.02030.0177--5.97--4.58-6.894.78-7.7256.39--258.50-357.76----0.0043--96.545.21179.13------
Noxopharm Ltd3.90m-12.13m23.38m1.00k--3.56--5.99-0.0415-0.04150.01340.02250.2684--1.643,901.84-83.43-50.96-94.78-62.98-----310.82-191.70---1.470.00--11.3244.0219.34------
Acrux Ltd14.46m-709.00k23.55m43.00--4.16--1.63-0.0024-0.00240.05020.01951.29--4.86---6.34-39.91-9.21-46.0072.38---4.90-132.53----0.2861--133.7428.2992.23---16.66--
Syntara Ltd9.83m-14.26m23.88m107.00--2.65--2.43-0.0197-0.01720.01360.00750.4421.582.22---64.13-27.33-97.76-34.2381.6988.37-145.11-61.991.75-262.590.0674--23.60-18.30-486.78---31.06--
Tryptamine Therapeutics Ltd1.21m-4.32m25.05m----3.72--20.75-0.0162-0.01620.00370.00620.2368-------84.69-66.34-120.26-79.70-----357.70-228.11---21.620.00---18.97138.7329.29--68.45--
Alterity Therapeutics Ltd123.46k-12.28m26.23m11.00--0.7951--212.42-0.005-0.0050.000050.00630.0044--1.5211,223.64-44.20-53.02-53.57-61.96-----9,947.97-40,995.62----0.0143--557.60-39.40-7.47---34.88--
Cann Group Ltd16.45m-29.28m27.12m40.00--0.5339--1.65-0.0724-0.07240.04060.11610.12370.39527.37---22.03-22.28-34.23-24.4321.11---178.07-407.570.0861-5.880.5646--114.9089.76-27.66---11.16--
Invion Ltd4.46m-1.50m32.12m8.00--1.80--7.20-0.0002-0.00020.00070.00280.2345--3.20---7.88-16.93-8.12-18.13-----33.60-51.63----0.00--25.7241.1827.95------
Data as of Jun 03 2024. Currency figures normalised to Alterity Therapeutics Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.